DE60231131D1 - Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose - Google Patents

Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose

Info

Publication number
DE60231131D1
DE60231131D1 DE60231131T DE60231131T DE60231131D1 DE 60231131 D1 DE60231131 D1 DE 60231131D1 DE 60231131 T DE60231131 T DE 60231131T DE 60231131 T DE60231131 T DE 60231131T DE 60231131 D1 DE60231131 D1 DE 60231131D1
Authority
DE
Germany
Prior art keywords
cop
vaccine
lateral sclerosis
amyotrophic lateral
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60231131T
Other languages
German (de)
English (en)
Inventor
Michal Eisenbach-Schwartz
Esther Yoles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE60231131D1 publication Critical patent/DE60231131D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DE60231131T 2001-12-06 2002-12-05 Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose Expired - Lifetime DE60231131D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33613901P 2001-12-06 2001-12-06
PCT/IL2002/000979 WO2003047500A2 (en) 2001-12-06 2002-12-05 Vaccine and method for treatment of motor neurone diseases

Publications (1)

Publication Number Publication Date
DE60231131D1 true DE60231131D1 (de) 2009-03-26

Family

ID=23314742

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60231131T Expired - Lifetime DE60231131D1 (de) 2001-12-06 2002-12-05 Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose

Country Status (23)

Country Link
US (1) US7351686B2 (enExample)
EP (1) EP1429800B1 (enExample)
JP (1) JP4542339B2 (enExample)
KR (1) KR20040081431A (enExample)
CN (2) CN1617736A (enExample)
AT (1) ATE422362T1 (enExample)
AU (1) AU2002353486B2 (enExample)
CA (1) CA2469092C (enExample)
CY (1) CY1109044T1 (enExample)
DE (1) DE60231131D1 (enExample)
DK (1) DK1429800T3 (enExample)
ES (1) ES2322566T3 (enExample)
HU (1) HU228207B1 (enExample)
IL (1) IL160105A0 (enExample)
IS (1) IS2670B (enExample)
MX (1) MXPA04005537A (enExample)
NO (1) NO336231B1 (enExample)
NZ (1) NZ533356A (enExample)
PL (1) PL205469B1 (enExample)
PT (1) PT1429800E (enExample)
RU (1) RU2303996C2 (enExample)
SI (1) SI1429800T1 (enExample)
WO (1) WO2003047500A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399740B2 (en) 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy
WO2004060265A2 (en) * 2003-01-07 2004-07-22 Yeda Research And Development Co. Ltd. Eye-drop vaccine containing copolymer 1 for therapeutic immunization
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
DK1701730T3 (da) 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
CA2565819A1 (en) * 2004-05-07 2005-12-01 Peptimmune, Inc. Methods of treating disease with random copolymers
JP5241012B2 (ja) * 2005-07-15 2013-07-17 ノバルティス アーゲー Ｐａｍｐｓ、病原体関連分子パターン
CN100448481C (zh) * 2006-06-22 2009-01-07 中国科学院遗传与发育生物学研究所 xCT蛋白及其编码基因的新用途
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
US9861686B2 (en) * 2011-12-05 2018-01-09 Ben-Gurion University Of The Negev Research & Development Authority Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (ALS)
KR20140145173A (ko) * 2012-03-26 2014-12-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 알츠하이머 질병 진단 및 알츠하이머 질병 진행 진단용 세포 마커
EP2892353A4 (en) 2012-09-10 2016-10-26 Yeda Res & Dev INDIVIDUALIZED IMMUNOMODULATION THERAPY FOR NEURODEGENERATIVE ILLNESSES, CNS LESIONS AND AGGREGATIVE DEMENTIA
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US3849650A (en) 1973-03-29 1974-11-19 Picker Corp Automatic x-ray inspection system
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
SE505316C2 (sv) * 1995-10-17 1997-08-04 Kenneth G Haglid Användning av proteinet S-100b för framställning av läkemedel för nervceller
RU2211697C2 (ru) * 1996-09-27 2003-09-10 Гилфорд Фармасьютикалз Инк. Способ лечения глутаматных расстройств
JP2002503658A (ja) * 1998-02-13 2002-02-05 オートイミューン インク ＣＯＰ−１及びＴｈ−２促進性サイトカインを使用した、多発性硬化症の治療
US20030108528A1 (en) 1998-05-19 2003-06-12 Michal Eisenbach-Schwartz Activated t-cells, nervous system-specific antigens and their uses
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1039929A1 (en) 1998-07-21 2000-10-04 YEDA RESEARCH AND DEVELOPMENT Co. Ltd. Activated t-cells and their uses
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
RU2155063C1 (ru) * 1999-10-20 2000-08-27 Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" Тетрапептид, стимулирующий функциональную активность нейронов, фармакологическое средство на его основе и способ его применения
HK1054507B (zh) * 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
DE60116467T2 (de) 2000-06-07 2006-11-02 Yeda Research And Development Co., Ltd. Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
WO2002076503A1 (en) * 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US6835711B2 (en) * 2001-06-28 2004-12-28 Yeda Research And Development Co. Ltd. Use of poly-Glu,Tyr for neuroprotective therapy
US7399740B2 (en) * 2001-06-28 2008-07-15 Yeda Research And Development Co. Ltd. Poly-Glu,Tyr for neuroprotective therapy

Also Published As

Publication number Publication date
WO2003047500A2 (en) 2003-06-12
AU2002353486B2 (en) 2009-01-15
EP1429800A2 (en) 2004-06-23
PL370070A1 (en) 2005-05-16
HK1067043A1 (en) 2005-04-01
IS2670B (is) 2010-09-15
CN102151330A (zh) 2011-08-17
IL160105A0 (en) 2004-06-20
DK1429800T3 (da) 2009-04-27
HUP0500039A2 (hu) 2005-03-29
SI1429800T1 (sl) 2009-08-31
ATE422362T1 (de) 2009-02-15
NZ533356A (en) 2006-10-27
JP4542339B2 (ja) 2010-09-15
ES2322566T3 (es) 2009-06-23
HU228207B1 (hu) 2013-01-28
CA2469092A1 (en) 2003-06-12
NO336231B1 (no) 2015-06-22
PT1429800E (pt) 2009-04-27
US7351686B2 (en) 2008-04-01
IS7296A (is) 2004-06-03
KR20040081431A (ko) 2004-09-21
CY1109044T1 (el) 2014-07-02
MXPA04005537A (es) 2004-11-01
NO20042833L (no) 2004-08-12
CA2469092C (en) 2013-02-19
RU2303996C2 (ru) 2007-08-10
US20050220802A1 (en) 2005-10-06
EP1429800B1 (en) 2009-02-11
CN1617736A (zh) 2005-05-18
EP1429800A4 (en) 2006-03-22
RU2004120536A (ru) 2005-03-27
AU2002353486A1 (en) 2003-06-17
WO2003047500A3 (en) 2004-03-18
CN102151330B (zh) 2017-04-12
HUP0500039A3 (en) 2010-01-28
PL205469B1 (pl) 2010-04-30
JP2005515198A (ja) 2005-05-26

Similar Documents

Publication Publication Date Title
ATE422362T1 (de) Vakzine und verwendung davon zur behandlung amyotrophischer lateralsklerose
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
DE69718150D1 (de) Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
EA200601132A1 (ru) Предупреждение и лечение амилоидогенного заболевания
ATE503490T1 (de) Monodisperse mischungen und verfahren zur behandlung von diabetes
SE9302308L (sv) Proteinberedning
DE60331049D1 (de) Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
ATE347376T1 (de) Behandlung von allergien
PL324531A1 (en) Derivatives of cyclosporin effective against hiv virus
MY129566A (en) A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance
DE60233898D1 (de) Transdermales therapeutisches system für parkinson-krankheit mit hohen rotigotin-plasmaspiegeln
DE69730476D1 (de) Albumin als aktiven bestandteil zur behandlung von bindehaut- und hornhautverletzungen und von trockenen augen
DE69628844D1 (de) Leishmania-antigene zur anwendung in der leishmaniasis therapie und diagnose
PT1079803E (pt) Formulacoes de proteinas
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
ATE152628T1 (de) Verwendung von parathormone, seinen biologisch aktiven fragmenten oder von verwandten peptiden zur behandlung von schwangerschaft
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
MXPA02011533A (es) Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona.
HU230002B1 (hu) L-karnitin alkalmazása proteinek stabilizálására szolgáló szerként
DE60212349D1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines pharmazeutischen mittels zur prävention und behandlung von sexuellen störungen
NO20034453D0 (no) Anvendelse av CD25-bindende molekyler i steroid-resistente pasienter
ATE420890T1 (de) Isoleucyl-valyl-threonyl-asparaginyl-threonyl- threonin (ivtntt) enthaltende biologisch wirksame peptide
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma
EA200200987A1 (ru) Лечение заболеваний, связанных с серотонинергической системой
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada

Legal Events

Date Code Title Description
8364 No opposition during term of opposition